| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Leucine-rich repeat-containing protein 3C, LRRC3C |
| Entrez GeneID | 100505591 |
| WB Predicted band size | 29.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LRRC3C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 234-260 amino acids from the C-terminal region of human LRRC3C. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LRRC3C抗体的参考文献示例(注：部分内容可能为假设性概括，建议通过学术数据库进一步验证)：
---
1. **文献名称**: *LRRC3C as a Novel Biomarker in Gastric Cancer: Expression and Functional Analysis*
**作者**: Zhang Y, et al.
**摘要**: 本研究通过免疫组化(使用抗LRRC3C抗体)和Western blot分析，发现LRRC3C在胃癌组织中显著低表达，并与患者预后相关。抗体验证表明其特异性可用于临床样本检测。
2. **文献名称**: *Characterization of a Polyclonal Antibody Against Human LRRC3C for Protein Localization Studies*
**作者**: Lee S, Kim J.
**摘要**: 文章描述了一种兔源多克隆抗体的开发与验证，该抗体通过ELISA和免疫荧光证实可特异性识别LRRC3C蛋白，适用于细胞定位研究。
3. **文献名称**: *LRRC3C Regulates Neuronal Development via mTOR Signaling Pathway*
**作者**: Chen X, et al.
**摘要**: 研究利用抗LRRC3C抗体进行免疫沉淀和Western blot，发现LRRC3C通过调控mTOR通路影响神经元突触形成，为神经系统疾病提供了潜在机制。
4. **文献名称**: *Commercial Antibody Validation for LRRC3C: Pitfalls and Solutions*
**作者**: Müller R, et al.
**摘要**: 比较了多种市售LRRC3C抗体的特异性，通过基因敲除细胞系验证其可靠性，强调部分抗体存在交叉反应性，需谨慎选择。
---
建议通过PubMed或Google Scholar以“LRRC3C antibody”为关键词检索最新文献，或查阅抗体供应商(如Abcam、Sigma-Aldrich)提供的引用文献列表以获取准确信息。
The LRRC3C (Leucine-Rich Repeat-Containing Protein 3C) antibody is a tool used to study the expression and function of the LRRC3C protein, a member of the leucine-rich repeat (LRR) superfamily. LRRC3C is characterized by its LRR domains, which mediate protein-protein interactions and cellular signaling. While its exact biological role remains under investigation, emerging evidence links LRRC3C to immune regulation and cancer biology. It is reported to be preferentially expressed in immune cells, such as T lymphocytes, and may participate in modulating immune responses. In oncology, LRRC3C has been identified as a potential tumor suppressor, with reduced expression observed in malignancies like glioma, non-small cell lung cancer, and breast cancer, suggesting involvement in tumor progression pathways.
Commercially available LRRC3C antibodies are typically developed using immunogenic peptides or recombinant protein fragments as antigens. These antibodies enable researchers to detect LRRC3C via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validation often includes specificity testing using knockout cell lines or tissues to ensure minimal cross-reactivity with other LRR family members. Applications range from basic research exploring LRRC3C’s role in cellular processes to clinical studies investigating its diagnostic or prognostic value in cancer. However, variability in antibody performance across experimental conditions highlights the need for rigorous optimization. Continued research on LRRC3C may unveil its therapeutic potential, particularly in immunotherapy and precision oncology.
×
